Viral hepatitis B during MIC

By Hajer Hassine

Immunosuppressants (IS) are a cornerstone of the management of inflammatory bowel disease (IBD), thereby increasing the risk of B-virus reactivation (rHVB). The prevalence of HBV infection among patients with IBD is higher than in the general population. Screening for HBV is mandatory in patients with IBD. In cases of IS treatment, HBV requires preemptive or, in some cases, prophylactic treatment depending on serostatus and the risk of reactivation. HBV vaccination is recommended for seronegative individuals.

• Format: Paperback
• Language: English
• ISBN: 6630136314
• ISBN13: 9786630136319
• Release Date: June 2026
• Publisher: Our Knowledge Publishing
• Length: 60 Pages
• Weight: 0.21 lbs.
• Dimensions: 0.1" x 6.0" x 9.0"